Europe Hepatitis Delta Virus Hdv Infection Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 20.50 Million |
 Taille du marché (année de prévision) |
USD 31.01 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen de l'infection par le virus de l'hépatite D (VHD), par type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie ( transplantation hépatique ) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatrique et pédiatrique), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire, et autres), canal de distribution (appel d'offres direct, ventes au détail, et autres) - Tendances et prévisions de l'industrie jusqu'en 2031
Analyse et perspectives du marché européen de l'infection par le virus de l'hépatite Delta (VHD)
La prévalence croissante de l'hépatite, en particulier de l'hépatite B, influence considérablement le marché européen de l'infection par le virus de l'hépatite delta (VHD). L'hépatite D est une infection du foie causée par le virus de l'hépatite D (VHD), qui nécessite la présence du virus de l'hépatite B (VHB) pour se répliquer. À mesure que les infections par l'hépatite B augmentent au niveau régional, le nombre de personnes susceptibles d'être infectées par le VHD augmente également. Ce nombre croissant de personnes infectées par le VHB crée une population cible plus large pour le VHD, ce qui stimule la demande de solutions diagnostiques et thérapeutiques spécifiques au VHD.
Data Bridge Market Research analyse que le marché européen de l'infection par le virus de l'hépatite Delta (HDV) devrait atteindre 31,01 millions USD d'ici 2031, contre 20,50 millions USD en 2023, avec un TCAC de 5,5 % au cours de la période de prévision de 2024 à 2031.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (personnalisable pour 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie (transplantation hépatique) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatriques et pédiatriques), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire, et autres), canal de distribution (appel d'offres direct, vente au détail, et autres) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Pays-Bas, Suisse, Russie, Belgique, Turquie, Danemark, Suède, Pologne, Norvège, Finlande, Reste de l'Europe |
|
Acteurs du marché couverts |
GILEAD SCIENCES, INC., GENENTECH, INC., ALNYLAM PHARMACEUTICALS, INC., ASSEMBLY BIOSCIENCES, INC., EIGER BIOPHARMACEUTICALS, GLOBEIMMUNE INC., HUAHUI HEALTH LTD., JOHNSON & JOHNSON SERVICES, INC., PHARMAESSENTIA CORPORATION, REPLICOR, VIR BIOTECHNOLOGY, INC. |
Définition du marché
Hepatitis Delta (HDV) infection is a rare but severe form of viral hepatitis that occurs when the Hepatitis Delta Virus (HDV) infects a liver already infected with Hepatitis B Virus (HBV). HDV is a defective virus that requires HBV to replicate and produce new viral particles, and it is characterized by its ability to rapidly cause liver disease, including acute hepatitis, liver failure, and even death. The coinfection of HBV and HDV leads to a more severe and rapid progression of liver disease compared to HBV infection alone, and it is often associated with higher levels of liver inflammation and fibrosis.
Europe Hepatitis Delta Virus (HDV) Infection Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Hepatitis
The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the Europe Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.
- Increase in Healthcare Expenditure
The increase in healthcare expenditure has a significant impact on the growth of the Europe Hepatitis Delta Virus (HDV) infection market by facilitating more substantial investment in diagnostic technologies and treatment options. As healthcare budgets expand, governments and healthcare organizations are able to allocate more resources towards advanced diagnostic tools for HDV. This investment leads to the development and deployment of more sensitive and accurate testing methods, which enhances early detection rates and drives up demand for diagnostic services. The improved availability of high-quality diagnostic tests contributes directly to market growth by increasing the overall testing and screening activities. Moreover, higher healthcare expenditure often translates into better access to and affordability of treatment options for HDV. As funding increases, there is greater potential for the development and distribution of innovative antiviral therapies and other medical interventions. This expanded access to effective treatments not only improves patient outcomes but also stimulates market growth by creating a more extensive patient base seeking treatment options. Enhanced therapeutic options can lead to better disease management and higher rates of treatment adherence, further boosting demand within the HDV infection market.
Opportunity
- Rising Innovative Drug Development
Pipeline therapies like JNJ-73763989 and Peginterferon Lambda are creating new opportunities for pharmaceutical companies to address the substantial unmet need for effective treatments in this space. JNJ-73763989 is a ground-breaking therapy designed to inhibit the replication of HDV by targeting essential components of the viral life cycle, offering a more precise and potentially effective approach compared to existing treatments. On the other hand, Peginterferon Lambda, a novel form of interferon therapy, is being evaluated for its ability to provide antiviral effects while minimizing the side effects traditionally associated with interferon-based treatments. Its targeted mechanism of action has the potential to improve patient outcomes by offering a more tolerable therapy option.
Restraint/Challenge
- Limited Awareness of Hepatitis Delta Virus (HDV)
Limited awareness of Hepatitis Delta Virus (HDV) infection is a significant restraint for the Europe HDV infection market. Many healthcare providers and patients are not aware of the risks and consequences of HDV infection, leading to delayed diagnosis and treatment. This lack of awareness results in patients being diagnosed with liver disease at an advanced stage, making treatment more challenging and increasing the risk of complications and mortality.
- Side Effects of Current Treatments
Pegylated interferon-alpha has been a key therapeutic option for managing HDV due to its ability to induce a sustained viral response. However, its use is hampered by a range of debilitating side effects that can significantly impact patient adherence to the treatment regimen.
Common side effects of pegylated interferon-alpha include flu-like symptoms such as fever, chills, and muscle aches, as well as more severe issues such as fatigue, gastrointestinal disturbances, and psychological effects including depression and anxiety. These side effects can be distressing for patients, often leading to reduced quality of life and difficulty in maintaining consistent treatment. The severity of these adverse effects can discourage patients from completing their prescribed course of therapy, resulting in suboptimal treatment outcomes and potential disease progression.
Recent Developments
- In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry
- In March 2024, Gilead Sciences Inc. completed the acquisition of CymaBay Therapeutics, gaining access to innovative therapies for liver and rare diseases. This acquisition expands Gilead’s research portfolio and strengthens its pipeline, enhancing its capacity to address unmet medical needs. The acquisition of CymaBay provides Gilead with promising new drug candidates and expertise in liver and rare diseases, boosting its research capabilities and expanding its therapeutic offerings
- In March 2024, Gilead Sciences, Inc. and Merus have announced a collaboration to discover novel antibody-based trispecific T-cell engagers, aiming to enhance cancer immunotherapy. This partnership combines Gilead’s expertise with Merus’ innovative technology to develop advanced treatments for cancer
- In March 2024, Alnylam Pharmaceuticals launched the Family Health History Road Trip to promote discussions on hereditary ATTR (hATTR) amyloidosis. Genealogist Bernice Bennett traveled cross-country to highlight the importance of family health history for earlier diagnosis
Europe Hepatitis Delta Virus (HDV) Infection Market Scope
The Europe Hepatitis Delta Virus (HDV) infection market is segmented into nine notable segments based on type, treatment, drug type, route of administration, age group, gender, transmission, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Acute Hepatitis D
- Chronic Hepatitis D
On the basis of type, the market is segmented into acute hepatitis D, chronic hepatitis D.
Treatment
- Surgery (Liver Transplant)
- Medication
On the basis of treatment, the market is segmented into surgery (liver transplant) and medication.
Drug Type
- Branded
- Generic
On the basis of drug type, the market is segmented into branded and generic.
Route of Administration
- Oral
- Parenteral
On the basis of route of administration, the market is segmented into oral and parenteral.
Age group
- Adults
- Geriatric
- Pediatric
On the basis of age group, the market is segmented into adults, geriatric, and pediatric.
Gender
- Female
- Male
On the basis of gender, the market is segmented into female and male.
Transmission
- Contaminated Needles
- Exposure to Infected Blood
- Blood and Plasma Product Transfusion
- Others
On the basis of transmission, the market is segmented into contaminated needles, exposure to infected blood, blood and plasma product transfusion and others.
End User
- Hospitals
- Specialty Clinics
- Home Care Setting
- Research Institutes and Academic Centers
- Ambulatory Surgical Centers
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, home care setting, research institutes and academic centers, ambulatory surgical centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché de l'infection par le virus de l'hépatite delta (VHD) en Europe
Le marché européen des infections par le virus de l’hépatite Delta (HDV) est segmenté en neuf segments notables en fonction du type, du traitement, de la voie d’administration, de la forme posologique, de la tranche d’âge, du sexe, de la transmission, de l’utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne, la Russie, les Pays-Bas, la Suisse, la Suède, la Belgique, le Danemark, la Norvège, la Finlande, la Pologne, la Turquie et le reste de l'Europe.
L'Allemagne devrait dominer le marché européen de l'infection par l'hépatite Delta (HDV), en raison de sa forte incidence de co-infection par le VHB et le VHD parmi les migrants en provenance d'Afrique subsaharienne, en particulier de pays comme Haïti et l'Afrique de l'Ouest, qui sont plus susceptibles de porter le virus en raison de la forte endémicité dans leur pays d'origine.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité de grandes entreprises de services et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des acteurs locaux et nationaux et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du virus de l'hépatite Delta (VHD) en Europe
Le paysage concurrentiel du marché européen de l'infection par l'hépatite Delta (HDV) fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Certains des principaux acteurs du marché opérant sur le marché sont Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc. et Alnylam Pharmaceuticals, Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 EUROPE CLINICAL TRIAL MARKET FOR EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
4.4 DISTRIBUTION OF PRODUCTS BY PHASE
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF HEPATITIS
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS
6.4.2 SLOW REGULATORY APPROVALS
7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 ACUTE HEPATITIS D
7.3 CHRONIC HEPATITIS D
8 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY (LIVER TRANSPLANT)
8.3 MEDICATION
8.3.1 APPROVED THERAPIES
8.3.1.1 PEGYLATED INTERFERON ALPHA
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)
8.3.2 EMERGING THERAPIES
9 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM
9.1 OVERVIEW
9.2 TABLET
9.3 CAPSULE
9.4 INJECTABLE
10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERIC
11 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 CAPSULE
11.2.3 OTHERS
11.3 PARENTERAL
12 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
13.4 PEDIATRIC
14 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
14.1 OVERVIEW
14.2 CONTAMINATED NEEDLES
14.3 EXPOSURE TO INFECTED BLOOD
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION
14.5 OTHERS
15 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CENTERS
15.4 HOME CARE SETTING
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
16.4 OTHERS
17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 NETHERLANDS
17.1.7 SWITZERLAND
17.1.8 RUSSIA
17.1.9 BELGIUM
17.1.10 TURKEY
17.1.11 DENMARK
17.1.12 SWEDEN
17.1.13 POLAND
17.1.14 NORWAY
17.1.15 FINLAND
17.1.16 REST OF EUROPE
18 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 GILEAD SCIENCES, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PIPELINE PRODUCT
20.1.5 RECENT DEVELOPMENTS
20.2 GENENTECH, INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 ALNYLAM PHARMACEUTICALS, INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PIPELINE PRODUCT
20.3.4 RECENT DEVELOPMENTS
20.4 ASSEMBLY BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PIPELINE PRODUCT
20.4.4 RECENT DEVELOPMENTS
20.5 EIGER BIOPHARMACEUTICALS
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 PIPELINE PRODUCT
20.5.6 RECENT DEVELOPMENT
20.6 GLOBEIMMUNE INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PRODUCT
20.6.3 RECENT DEVELOPMENT
20.7 HUAHUI HEALTH LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 PIPELINE PRODUCT
20.7.3 RECENT DEVELOPMENT
20.8 JOHNSON & JOHNSON SERVICES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PIPELINE PRODUCT
20.8.4 RECENT DEVELOPMENT
20.9 PHARMAESSENTIA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PIPELINE PRODUCT
20.9.4 RECENT DEVELOPMENT
20.1 REPLICOR
20.10.1 COMPANY SNAPSHOT
20.10.2 PIPELINE PRODUCT
20.10.3 RECENT DEVELOPMENTS
20.11 VIR BIOTECHNOLOGY, INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALAYSIS
20.11.3 PRODUCT PIPELINE
20.11.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 EMERGING NOVEL THERAPIES FOR HDV
TABLE 2 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 EUROPE ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 EUROPE CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 EUROPE SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 11 EUROPE TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 EUROPE CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 EUROPE INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 EUROPE BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 EUROPE GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 EUROPE PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 EUROPE FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 EUROPE MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 25 EUROPE ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 EUROPE GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 EUROPE PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 29 EUROPE CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 EUROPE EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 EUROPE BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 EUROPE HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 EUROPE SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 EUROPE HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 EUROPE RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 EUROPE AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 41 EUROPE DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 EUROPE OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 49 EUROPE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 EUROPE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 53 EUROPE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 57 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 63 GERMANY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 GERMANY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 67 GERMANY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 69 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 70 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 72 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 73 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 74 GERMANY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 77 FRANCE MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 FRANCE APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 FRANCE ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 83 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 84 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 85 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 86 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 87 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 88 FRANCE RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 91 U.K. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 U.K. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 U.K. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 97 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 98 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 99 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 100 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 U.K. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 102 U.K. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 105 ITALY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 ITALY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 108 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 109 ITALY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 111 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 112 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 113 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 114 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 115 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 ITALY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 119 SPAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 SPAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 123 SPAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 125 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 126 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 127 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 128 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 130 SPAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 131 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 133 NETHERLANDS MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 NETHERLANDS APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 136 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 137 NETHERLANDS ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 139 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 140 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 141 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 142 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 143 NETHERLANDS HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 144 NETHERLANDS RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 147 SWITZERLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 SWITZERLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 151 SWITZERLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 153 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 154 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 155 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 156 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 157 SWITZERLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 SWITZERLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 161 RUSSIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 RUSSIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 165 RUSSIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 167 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 168 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 169 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 170 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 171 RUSSIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 172 RUSSIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 175 BELGIUM MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 BELGIUM APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 179 BELGIUM ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 181 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 182 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 183 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 184 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 185 BELGIUM HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 186 BELGIUM RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 189 TURKEY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 TURKEY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 193 TURKEY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 195 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 196 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 197 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 198 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 199 TURKEY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 200 TURKEY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 203 DENMARK MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 204 DENMARK APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 207 DENMARK ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 208 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 209 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 210 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 211 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 212 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 213 DENMARK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 214 DENMARK RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 217 SWEDEN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 218 SWEDEN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 221 SWEDEN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 223 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 224 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 225 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 226 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 227 SWEDEN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 SWEDEN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 231 POLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 POLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 234 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 235 POLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 237 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 238 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 239 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 240 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 241 POLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 242 POLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 245 NORWAY MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 NORWAY APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 249 NORWAY ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 251 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 252 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 253 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 254 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 255 NORWAY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 256 NORWAY RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 258 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 259 FINLAND MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 FINLAND APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 263 FINLAND ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 265 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 266 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 267 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 268 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 FINLAND HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 270 FINLAND RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 2 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 15 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023
FIGURE 16 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 17 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 18 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023
FIGURE 20 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 21 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 22 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 23 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023
FIGURE 24 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 25 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 26 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023
FIGURE 28 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 29 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 30 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 31 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 32 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 33 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 34 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023
FIGURE 36 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 37 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023
FIGURE 40 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 41 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 42 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023
FIGURE 44 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)
FIGURE 45 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)
FIGURE 46 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 47 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023
FIGURE 48 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 49 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 52 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 53 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 54 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)
FIGURE 56 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
